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Ovarian cancer cellsDrug resistance is the major cause of failure of cancer chemotherapy in ovarian cancer. However, the molecular
mechanisms on the regulation of drug resistance are not fully understood. Herewe showed that Trx1 and FOXO1
were involved in paclitaxel (PTX)-induced drug resistance in ovarian cancer A2780 cells. PTX induced reactive
oxygen species (ROS) and resulted in Trx1 and FOXO1 nuclear translocation. We further found that Trx1
bound to FOXO1 and enhanced FOXO1 transcriptional activity; however Trx1 C69S mutant which is barely
detected in the nucleus downregulated Trx1–FOXO1 interaction and Trx1-induced FOXO1 transcriptional
activation. Silencing of FOXO1 abrogated Trx1-induced drug resistance. Trx1 increased FOXO1-induced drug
resistance, while Trx1 C69S mutant completely abolished the regulation of FOXO1-mediated drug resistance
by Trx1. These ﬁndings provided a novel mechanism on Trx1/FOXO1 signaling in drug resistance in ovarian
cancer cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Ovarian carcinoma is the major cause of gynecological cancer-
related mortality worldwide. The main limitation to a successful
treatment for ovarian cancer is the development of drug resistance [1].
Several mechanisms on drug resistance in cancer have been elucidated,
including increased DNA repair [2] and overexpression of drug efﬂux
transporters, such as P-glycoprotein (P-gp) [3,4] and antiapoptotic
proteins, such as Bcl-2 [5]. However the precise molecular mechanisms
underlying drug resistance in ovarian cancer are far from fully
elucidated.
Thioredoxin 1 (Trx1), a ubiquitously expressed small redox protein
which has a conserved Cys-Gly-Pro-Cys redox catalytic site, plays criti-
cal roles in the regulation of cellular redox homeostasis [6]. Trx1 levels
have been found to be overexpressed in awide variety of human tumorsedoxin 1; P-gp, P-glycoprotein;
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86 27 87792147; fax: +86 27including ovarian cancer [7–9]. Elevated Trx1 is associated with in-
creased tumor cell proliferation [10,11], inhibition of spontaneous
and drug-induced apoptosis [12,13], aggressive tumor growth and
decreased patient survival [14], which makes Trx1 an attractive tar-
get for cancer therapy [15]. It has been shown that Trx1 might reg-
ulate cell survival by activating a number of transcription factors,
such as NF-κB and AP-1 [16]. Trx1 also has been reported to bind
to, and thus inhibit proapoptotic proteins including apoptosis signal
regulating kinase-1 (Ask-1) [17] and the tumor suppressor PTEN, a
protein which antagonizes the activity of the PI3K/Akt pathway
[18].
Forkhead box Class O (FOXO) proteins, which include FOXO1
(FKHR), FOXO3a (FKHRL1), FOXO4 (AFX) and FOXO6 in humans,
act downstream of the PI3K/Akt pathway and are involved in vari-
ous cellular processes including cell cycle arrest, differentiation,
apoptosis and resistance to oxidative stress and DNA damage [19].
FOXO function is modulated by phosphorylation, acetylation,
ubiquitination and protein–protein interactions, which affects
nuclear-cytoplasmic translocation, DNA binding and ultimately tar-
get gene expression [20]. Recent papers showed that FOXO proteins
played an important role in protection of cancer cells against
chemotherapy-induced apoptosis [21–24]. For example, Goto T
et al. reported that FOXO1 contributed to paclitaxel (PTX)-induced
drug resistance in ovarian cancer [24]. In the present study, we
showed that the role of FOXO1 in PTX resistance was positively
regulated by Trx1 through a protein–protein interaction and the
effects might depend on Trx1 nuclear translocation which was
mediated by PTX-induced reactive oxygen species (ROS) in ovarian
cancer cells.
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2.1. Cell culture
The human ovarian cancer cell line A2780 was kindly provided by
Dr. Ding Ma (Huazhong University of Science and Technology, Wuhan,
China). The PTX-resistant A2780 cells (A2780/PTX) were purchased
from KeyGen Biotech Co. Ltd (Nanjing, China). A2780 cells were
cultured in RPMI 1640 medium and A2780/PTX cells were cultured in
RPMI 1640 medium containing 900 nM PTX at 37 °C in 5% CO2
atmosphere. All media contained 10% FBS, 100 U/ml penicillin and
100 μg/ml streptomycin.2.2. Plasmids, short hairpin RNAs (shRNAs), and chemicals
Plasmids for wild type FLAG–FOXO1, V5–FOXO1, the Renilla lucifer-
ase reporter vector and the luciferase reporter construct, 3 × IRS, which
contains three copies of the FOXO response element in the promoter of
the IGFBP1 gene were kindly provided by Dr. Haojie Huang (Mayo
Clinic, Rochester, MO, USA). Constructs for GST–FOXO1 recombinant
proteins were described earlier [25]. The full-length cDNA of Trx1 was
ampliﬁed from A2780 cells and then cloned into pcDNA3.1 (Invitrogen,
Carlsbad, CA, USA) and p3 × FLAG-CMV-7.1 (Sigma-Aldrich, St Louis,
MO, USA). Plasmids expressing Trx1 C69S and Trx1 C32/35S were
generated by PCR-based mutagenesis according to the manufacturer's
instruction (Stratagene, La Jolla, CA, USA) and veriﬁed by sequencing.
For construction of Trx1 shRNA and FOXO1 shRNA plasmids, sequences
used to knock down endogenous Trx1 (5′-ATGACTGTCAGGATGTTGC-
3′) and FOXO1 (5′-CCAGATGCCTATACAAACA-3′) were inserted into
pCMS4-H1p-EGFP which contains an H1 promoter for shRNA expres-
sion, a CMV promoter for expression of shRNA-resistant cDNAs, and
an SV40 promoter controlling EGFP expression and then identiﬁed by
sequencing [26]. PTXwas purchased fromTaihuaNatural Plant Pharma-
ceutical Co. Ltd (Xi'an, China).2.3. Gene transfection and luciferase reporter assay
Transient transfection of the cells was done by electroporation as
described [25]. Transfection efﬁciencies (~75–90%) were routinely
achieved. For luciferase reporter assays for FOXO1 transcriptional activ-
ity [25], cells were transfected with the indicated plasmids in combina-
tion with plasmids for 3 × IRS-Luc ﬁreﬂy and Renilla luciferase reporter
genes. After 36 h transfection, cells were harvested and the activities of
ﬁreﬂy and Renilla luciferase in cell lysates were measured using the
Dual-Luciferase reporter assay system (Promega, Madison, WI, USA).
Renilla luciferase activities of cells were used as internal control.2.4. Trx1 activity assay
The activity of Trx1 in cell lysates was determined using insulin
disulﬁdes as substrate [27]. Brieﬂy, 30 μg of sample proteins was pre-
incubated with 1 μl of 1 mM DTT at 37 °C for 20 min. The samples
were then incubated with buffer containing 85 mM HEPES (pH
7.5), 660 μM NADPH, 3 mM EDTA, 0.3 mM insulin and 0.08 unit (as
deﬁned by the manufacturer) of rat recombinant Trx reductase
(TrxR, Sigma-Aldrich, St Louis, MO, USA) at 37 °C for 2 h in a total
volume of 50 μl. For each sample, a blank containing all reagents except
TrxR was incubated and treated in the same manner. The reaction was
terminated by addition of 0.5 ml of 8 M guanidine-HCl and 0.4 mg/ml
of 5,5′-dithio-bis(2-nitrobenzioic) acid (DTNB) in 0.2 M Tris–Cl (pH
8.0). Absorbance at 412 nm was measured with a UV–VIS spectropho-
tometer (Beijing Purkinje General Instrument Co., Ltd., Beijing, China)
and the absorbance of the blankwas subtracted from that of the sample.2.5. Measurement of ROS generation
Intracellular ROS levels were measured using the oxidant-sensitive
ﬂuorogenic probe 2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCF-
DA) (Molecular Probes, Eugene, OR, USA) [28]. Brieﬂy, after treatment
with different concentrations of PTX for 24 h, the cells were stained
with 10 μM H2DCF-DA in phosphate buffered saline (PBS) at 37 °C for
30 min, then washed with PBS twice to remove the extracellular
H2DCF-DA. The intracellular ROS were analyzed with F-4500 ﬂuores-
cence spectrophotometer (Hitachi Ltd., Tokyo, Japan).2.6. Hydrogen peroxide (H2O2) measurement
Extracellular H2O2 was detected using Amplex Red Hydrogen
Peroxide/Peroxidase assay kit (Invitrogen, Carlsbad, CA, USA) [29].
Brieﬂy, after treatment with different concentrations of PTX for 24 h,
cells were suspended in Krebs–Ringer phosphate glucose (KRPG;
145 mM NaCl, 5.7 mM sodium phosphate, 4.86 mM KCl, 0.54 mM
CaCl2, 1.22 mM MgSO4 and 5.5 mM D-glucose, pH 7.35) containing
Amplex red reagent. Fluorescence was measured with excitation at
530 nm and emission at 590 nmusing a FlexStation 3microplate reader
(Molecular Devices, Sunnyvale, CA, USA) at 37 °C.2.7. Detection of intracellular superoxide formation
Superoxide levels were quantiﬁed using high performance liquid
chromatography (HPLC) analysis of 2-hydroxyethidium formation as
described [30]. Brieﬂy, after treatment with different concentrations of
PTX for 24 h, the cells were washed with PBS and then treated with
10 μM dihydroethidium (DHE, Sigma-Aldrich, St Louis, MO, USA) in
the dark for 30 min. The cells were harvested and cell pellets were
lysed in 250 μl lysis buffer (0.1% Triton X-100 in PBS, pH7.4). After n-
butanol extraction and drying in 100% N2, sample residues were
reconstituted in 100 μl H2O, centrifuged and the supernatants were
transferred to amber-colored HPLC vials for HPLC analysis. Typically,
50 μl of sample was injected into the HPLC system (HP 1100, Agilent
Technologies, Palo Alto, CA, USA) with a C-18 reverse phase column
(Supelco Nucleosil C18, 250 mm × 4.6 mm, 5 μm, 120 Å; Sigma-
Aldrich, St Louis, MO, USA) equilibrated with 10% acetonitrile in 0.1%
triﬂuoroacetic acid (TFA) solution. Hydroethidine, ethidium and 2-
hydroxyethidium were separated by a linear increase in acetonitrile
concentration. The elution was monitored by a variable UV detector at
210 and 350 nm and a ﬂuorescence detector with excitation and emis-
sion at 510 and 595 nm, respectively. The peak area corresponding to 2-
hydroxyethidium formationwas quantiﬁed and correctedwith the pro-
tein concentration of the sample. The protein content was determined
using the BCA protein assay kit (Beyotime Institute of Biotechnology,
China) according to the manufacturer's instructions.2.8. Cell cytotoxicity assay
Cell cytotoxicity was determined using a standard 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay [31].
Brieﬂy, cells were transfected with the indicated plasmids. After
48 h transfection, the cells were plated in 96-well plates at a density
of 5 × 103 cells per well. The cells were treatedwith different concen-
trations of PTX for 24 h. The cells were washed with PBS and then
20 μl of 5 mg/ml MTT solution was added to the cells in each well.
Plates were incubated for an additional 2 h at 37 °C. The medium
containing MTT was removed and 150 μl of DMSO was added to dis-
solve the formazan crystals formed by living cells. Absorbance was
measured at 490 nm using a Labsystems iEMS microplate reader
(Helsinki, Finland).
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The apoptosis induced by PTXwas detected using propidium iodide
(PI) staining [32]. Brieﬂy, A2780 cells were transfectedwith the indicat-
ed plasmids. At 36 h after transfection, the cells were treated with
25 nM PTX. After 24 h treatment, the cells were collected and washed
with PBS. After ﬁxation with 70% ethanol, cells were washed twice
with PBS and stained with a solution containing 20 μg/ml PI and 50
ug/ml RNase A. Cells were incubated for 30 min at room temperature
and sub-G1 cells were measured using a CytomicsTM FC 500 ﬂow
cytometer (Beckman Coulter, Fullerton, CA, USA).
2.10. GST recombinant protein puriﬁcation and GST-pull down assay
GST protein and GST–FOXO1 recombinant proteins were expressed
in BL21 Star (DE3) Escherichia coli strain (Invitrogen, Carlsbad, CA,
USA) and puriﬁed with glutathione-agarose beads (Sigma-Aldrich, St
Louis, MO, USA). GST-pull down assay was performed as described
[25]. Brieﬂy, approximately 10 μg of GST fusion proteins was incubated
with 50 μg of A2780/PTX cell lysates overnight at 4 °C. Protein com-
plexes were collected on glutathione-agarose beads and evaluated by
western blotting.
2.11. Immunoprecipitation, western blotting, immunoﬂuorescence staining
and antibodies
Protein immunoprecipitations were carried out using an immuno-
precipitation kit (Roche Applied Science, Mannheim, Germany) as de-
scribed [25]. Western blotting and immunoﬂuorescence staining were
performed as described [25]. The antibodies used were anti-FOXO1
and anti-PARP (Cell Signaling Technology, Danvers, MA, USA); anti-
FLAG (M2) (Sigma-Aldrich, St Louis, MO, USA); anti-Trx1 and anti-β-
actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-V5
(Invitrogen, Carlsbad, CA, USA).
2.12. Quantitative real-time reverse transcription-polymerase chain
reaction (qRT-PCR)
Total cellular RNAs were isolated from transfected cells using Trizol
(Invitrogen, Carlsbad, CA, USA), and cDNAs were synthesized using
SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). PCR
was done using primers speciﬁc for catalase (forward 5′-AGAGGAAACG
TCTGTGTGAGAACA-3′ and reverse 5′-TGACCGCTTTCTTCTGGATGA-3′),
manganese superoxide dismutase (MnSOD, forward 5′-GGCCTGATTA
TCTAA AAGCTATTTGG-3′ and reverse 5′-CGATCGTGGTTTACTTTTTGCA-
3′), GADD45 (forward 5′-CCATGCAGGAAGGAAAACTATG-3′ and reverse
5′-CCCAAACTATGGC TGCACACT-3′), and glyceraldehyde-3-phosphate
dehydrogenase (forward 5′-GAAGGT GAAGGTCGGAGTC-3′ and reverse
5′-GA AGATGGTGATGGGATTTC-3′). Expression levels of genes exam-
inedwere determined using a SYBR Green Supermix (Bio-Rad, Hercules,
CA, USA) on an iCycler iQ platform (Bio-Rad, Hercules, CA, USA) accord-
ing to the manufacturer's protocol [33]. Reactions were carried out in
triplicate and gene expression levels were normalized against
glyceraldehyde-3-phosphate dehydrogenase.
2.13. Chromatin immunoprecipitation (ChIP) assay
A2780 cells were transfected with the indicated plasmids. At 48 h
after transfection, the cells were crosslinked with 1% formaldehyde
and subjected to ChIP assay as previously described [33]. The soluble
chromatin was incubated with 2 μg of anti-FLAG (M2) or control
mouse IgG overnight. The ChIP DNA was extracted with a PCR puriﬁca-
tion kit (Invitrogen, Carlsbad, CA, USA) and subjected to PCR ampliﬁca-
tion using the primers speciﬁc for the FOXO1 binding region in the
promoter of MnSOD (forward 5′-TCTGACGTCTGTAAACAAGCCCAG-3′and reverse 5′-TTCTTTCCTGCGCTGTCTTGTAGC-3′). The PCR products
were analyzed by 2% agarose gels and stained with ethidium bromide.
2.14. Statistics
Experiments were carried out with three or four replicates. Statisti-
cal analyses were performed by Student's t test. Values with P b 0.05
are considered signiﬁcant.
3. Results
3.1. Trx1 and FOXO1 are involved in drug resistance in ovarian cancer cells
To explore the molecular pathways involved in drug resistance in
ovarian cancer, the PTX-sensitive human ovarian cancer A2780 cells
and the PTX-resistant A2780 cells (A2780/PTX) were used. As one
might expect, the IC50 value of PTX in A2780/PTX cells was about 570-
fold higher than that in A2780 cells [34], conﬁrming that A2780/PTX
cells possessed considerably higher drug resistance to PTX compared
with A2780 cells. As shown in Fig. S1, A2780/PTX cells expressed
increased levels of Trx1 and FOXO1 relative to parental A2780 cells. Cor-
respondingly, Trx1 and FOXO1protein levelsweremarkedly induced by
PTX in a dose-dependent manner at 48 h after treatment in A2780 cells
(Fig. 1A). However, PTX-stimulated expressions of Trx1 and FOXO1
were very limited in A2780/PTX cells (Fig. 1B). Furthermore, the activ-
ities of Trx1 and FOXO1 were also found to be upregulated in response
to PTX treatment in A2780 cells, but not in A2780/PTX cells (Fig. 1C and
D). These data indicated that the induction of Trx1 and FOXO1 might
correlate with drug resistance in ovarian cancer cells.
To further verify whether drug resistance in ovarian cancer wasme-
diated by Trx1 or FOXO1, the effects of Trx1 shRNA and FOXO1 shRNA
on the drug response of A2780/PTX cells were evaluated. As shown in
Fig. 1E and F, silencing of Trx1 or FOXO1 signiﬁcantly decreased the
cell viability of A2780/PTX cells in response to PTX treatment compared
with control shRNA, conﬁrming that FOXO1 and Trx1 were important
mediators in drug resistance in ovarian cancer cells.
3.2. ROS are involved in PTX-induced cytotoxicity in ovarian cancer cells
Low levels of ROS have been implicated as intracellular signaling
molecules in cellular processes such as proliferation, apoptosis and
senescence [35]. As shown in Fig. 2A, PTX treatment signiﬁcantly
increased total intracellular ROS detected by H2DCF-DA in A2780 cells.
Accordingly, there was a marked increase in the generation of extracel-
lular H2O2 and intracellular superoxide in PTX-treated A2780 cells
(Fig. 2B and C). However, no signiﬁcant difference in total intracellular
ROS, extracellular H2O2 and intracellular superoxide was observed
when A2780/PTX cells were treated with PTX, suggesting that ROS
might be involved in PTX-induced cell death in ovarian cancer cells. To
further conﬁrm the role of ROS in PTX-induced cytotoxicity in A2780
cells, the effects of N-acetyl-cysteine (NAC), a powerful antioxidant
and free radical scavenger, on PTX-induced ROS generation and cyto-
toxicity were examined. As shown in Fig. 2D and E, co-treatment with
NAC fully reversed PTX-induced increase in ROS and cytotoxicity in
A2780 cells. These data indicated that ROS played an important role in
PTX-induced cytotoxicity in A2780 cells.
3.3. PTX-induced ROS cause the activation and nuclear translocation of Trx1
and FOXO1 in ovarian cancer cells
To explore the role of ROS in Trx1- or FOXO1-mediated drug resis-
tance in ovarian cancer, the effects of PTX-induced ROS on the activities
of Trx1 and FOXO1 were ﬁrstly examined in A2780 cells. As shown in
Fig. 3A and B, PTX increased the activities of Trx1 and FOXO1 in A2780
cells, while co-treatment with NAC abolished the upregulation of Trx1
and FOXO1 activities induced by PTX. Furthermore the effects of PTX-
Fig. 1. Trx1 and FOXO1 confer PTX resistance in ovarian cancer cells. (A, B) Induction of Trx1 and FOXO1 protein expressions by PTX treatment in A2780 and A2780/PTX cells. A2780 cells
(A) and A2780/PTX cells (B) were treated with different concentrations of PTX for 24 h. The cells were harvested and subjected to western blotting analysis for expression of Trx1 and
FOXO1 proteins. β-actin was used as a loading control. Results from one representative experiment were shown on the left. Quantitative results were shown on the right. Data as
mean values ± S.D. (n = 3). *P b 0.01. (C, D) Induction of Trx1 and FOXO1 activities by PTX treatment in A2780 and A2780/PTX cells. A2780 cells and A2780/PTX cells were treated
with different concentrations of PTX for 24 h. The cells were harvested and the activities of Trx1 (C) and FOXO1 (D) were determined by insulin assay and luciferase reporter assay, re-
spectively. Error bars indicated S.D. among three individual experiments. *P b 0.05, **P b 0.01 compared with control group. (E, F) Effects of knocking down Trx1 or FOXO1 on the viability
of A2780/PTX cells in response to PTX treatment. A2780/PTX cells were transfected with control shRNA, Trx1 shRNA (E) or FOXO1 shRNA (F). At 48 h after transfection, the cells were
treated with different concentrations of PTX for 24 h and the cell viability was measured using MTT assay. Error bars indicated S.D. among three individual experiments. *P b 0.05,
**P b 0.01 compared with control shRNA group at the corresponding PTX concentration. The inserts showed the protein expression of Trx1 or FOXO1 after transfection with Trx1
shRNA or FOXO1 shRNA.
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termined by immunoﬂuorescence staining considering that nuclear
translocation was an indicator of the activation of FOXO1 and Trx1 pro-
teins [19,36]. As shown in Fig. 3C and D, endogenous Trx1 and FOXO1
were localized in both the nucleus and the cytosol in A2780 cells. How-
ever, more Trx1 and FOXO1were localized in nucleuswhen A2780 cells
were treated with PTX. Moreover, co-treatment with NAC inhibited the
nuclear translocation of Trx1 and FOXO1 induced by PTX. These data
suggested that PTX-induced ROS resulted in the activation and nuclear
translocation of Trx1 and FOXO1 in ovarian cancer cells.3.4. Trx1 increases FOXO1 transcriptional activity in ovarian cancer cells
Given that both Trx1 and FOXO1 were responsible for drug resis-
tance in ovarian cancer cells, we attempted to explore whether Trx1
and FOXO1 were likely to be involved in the same signaling pathway
leading to drug resistance. To test this notion, the effects of Trx1 on
FOXO1 transcriptional activitywere determined using a FOXO luciferase
reporter gene that contains three copies of forkhead response elements.
As shown in Fig. 4A, forced expression of Trx1 enhanced the transcrip-
tional activity of both endogenous FOXO1 and exogenous FOXO1 in a
Fig. 2. ROS are involved in PTX-induced cytotoxicity in ovarian cancer cells. (A–C) Effects of PTX on the production of total intracellular ROS, extracellular H2O2 and intracellular superoxide
in A2780 and A2780/PTX cells. The cells were treated with different concentrations of PTX for 24 h. The cells were harvested, and total intracellular ROS (A), extracellular H2O2 (B) and
intracellular superoxide (C) were determined using H2DCF-DA staining, Amplex Red Hydrogen Peroxide/Peroxidase assay and HPLC, respectively. Error bars indicated S.D. among
three individual experiments. *P b 0.01 compared with control group. (D, E) Effects of NAC on the PTX-induced intracellular ROS and cytotoxicity in A2780 cells. The cells were treated
with 10 nM PTX in the presence or absence of 3.2 mM NAC for 24 h. Intracellular ROS (D) and cytotoxicity (E) were determined using H2DCF-DA staining and MTT assay, respectively.
Error bars indicate S.D. among three individual experiments.*P b 0.01.
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by Trx1 shRNA inhibited the endogenous and exogenous FOXO1 tran-
scriptional activities (Fig. S2). However overexpression of Trx1 or
knocking down Trx1 did not affect FOXO1 protein expression (Fig. 4A
and S2), indicating that Trx1 increased FOXO1 transcriptional activity
independent of its protein expression change.
Trx1 was known to act as an important redox regulatory factor. To
determine whether the redox status of Trx1 was important for regulat-
ing FOXO1 transcriptional activity, the effects of overexpression of Trx1
C32/35S mutant, in which the redox regulatory domain (cysteine 32
and 35) was mutated to serine, on the transcriptional activity of
FOXO1 were determined. As shown in Fig. S3, overexpression of Trx1
C32/35S mutant did not affect FOXO1 transcriptional activity, suggest-
ing that Trx1-induced FOXO1 transcriptional activation was not depen-
dent on Trx1 redox activity. Interestingly, overexpression of Trx1 C69S
mutant, in which cysteine 69 was mutated to serine, was found to sig-
niﬁcantly abrogate the upregulation of FOXO1 transcriptional activity
(Fig. 4B). It was reported that cysteine residue at position 69 of Trx1
had two major functions: (1) Cysteine 69 contributed to the redox reg-
ulatory functions of Trx1 [37]; (2) Trx1 was S-nitrosylated on cysteine
69 and Trx1 C69S mutant was barely detected in the nucleus [38]. Con-
sidering that Trx1 redox activity was irrelevant to FOXO1 transcription-
al activation, Trx1-mediated FOXO1 transcriptional activation might
depend on the nuclear import of Trx1. Indeed, very few Trx1 C69S mu-
tant was detected in the nucleuswhen A2780 cells were incubatedwith
or without PTX treatment (Fig. S4).
3.5. Trx1 interacts with FOXO1
To examine the molecular mechanism responsible for Trx1-
mediated upregulation of FOXO1 transcriptional activity, we sought to
determine whether Trx1 physically interacted with FOXO1. Co-immunoprecipitation assays showed that endogenous Trx1 formed a
protein complex with endogenous FOXO1 in A2780 cells. This interac-
tion increased in response to PTX treatment while co-treatment with
NAC decreased the interaction between Trx1 and FOXO1 (Fig. 5A),
which suggested that Trx1 interacted with FOXO1 in A2780 cells and
this interaction might be regulated by PTX-induced ROS. Furthermore,
ectopically expressed FLAG-tagged Trx1 formed a complex with V5-
tagged FOXO1 in A2780 cells (Fig. 5B). Consistent with our ﬁndings
that Trx1 C69S mutant abolished the upregulation of FOXO1 transcrip-
tional activity, the interaction between Trx1 C69S mutant (FLAG–Trx1
C69S) and V5–FOXO1 decreased compared with the complex of
FLAG–Trx1/V5–FOXO1 (Fig. 5B). To examine whether Trx1 interacted
directly with FOXO1, ﬁve GST–FOXO1 fusion proteins were puriﬁed
(Fig. 5C, left and bottom right) and incubated with lysates of A2780/
PTX cells. As shown in Fig. 5C (top right), Trx1 were specially pulled
down by GST–FOXO1 fusion proteins FO1-3 and FO1-4, which
encompassed amino acids 211-419 and 354-503 in FOXO1, respectively.
As a negative control, no interaction between Trx1 and GST proteins
was observed. Considering that PTX-induced ROS induced Trx1 nuclear
translocation and Trx1 C69Smutant was barely detected in the nucleus,
the results indicated that Trx1 interacted directly with FOXO1 and the
interaction might be associated with Trx1 nuclear translocation.
3.6. Trx1 increases expression of endogenous genes regulated by FOXO1
FOXO transcription factors are critical for the regulation of cellular
response to stress stimuli by transactivating a series of target genes.
For example, FOXOs activate GADD45 involved in DNA damage repair,
MnSOD and catalase in ROS detoxiﬁcation [19]. To conﬁrm the upregu-
lation of FOXO1 activity mediated by Trx1, the effects of Trx1 on the ex-
pression of FOXO1 target genes were determined by qRT-PCR. As
expected, overexpression of FOXO1 resulted in the increase of MnSOD,
Fig. 3. PTX-induced ROS promote the activation and nuclear translocation of Trx1 and FOXO1 in A2780 cells. (A, B) Effects of NAC on the activities of Trx1 and FOXO1 in A2780 cells. The
cells were treated with 10 nM PTX in the presence or absence of 3.2 mMNAC for 24 h. The cells were harvested, and the activities of Trx1 (A) and FOXO1 (B) were determined by insulin
assay and luciferase reporter assay, respectively. Error bars indicated S.D. among three individual experiments. *P b 0.01. (C, D) Effects of NAC on the nuclear translocation of Trx1 and
FOXO1 induced by PTX in A2780 cells. A2780 cells were treated with 10 nM PTX in the presence or absence of 3.2 mM NAC. After 24 h treatment, immunoﬂuorescence chemistry was
performed using anti-Trx1 (red) to detect endogenous Trx1 expression (C) and anti-FOXO1 antibody (green) to detect endogenous FOXO1 expression (D). DAPI was used to stain nuclei.
Representative confocal microscopy images of intracellular distribution of Trx1 and FOXO1 were shown on the left. The scale bars represented 25 μm for C and 10 μm for D. The
quantiﬁcation of cell fractionation was shown in bar graphs on the right. Error bars indicated S.D. among three individual experiments. C, cells in which Trx1 or FOXO1 was only located
in cytoplasm; N, cells in which Trx1 or FOXO1 was only located in nucleus; C + N, cells in which Trx1 or FOXO1 was located in both cytoplasm and nucleus.
Fig. 4. Trx1 upregulates FOXO1 transcriptional activity. (A) Effects of Trx1 overexpression on the transcriptional activity of FOXO1. (B) Effects of Trx1 C69S mutant on the transcriptional
activity of FOXO1. A2780 cells were transfected with ﬁreﬂy and Renilla luciferase reporter constructs in combination with the plasmids as indicated. At 36 h after transfection, cells were
subjected to luciferase activity measurement (upper panel) or western blotting analysis (lower panel). Error bars indicate S.D. among three individual experiments.*P b 0.05.
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Fig. 5. Trx1 interacts with FOXO1. (A) Interaction of endogenous Trx1 and FOXO1 proteins in A2780 cells. A2780 cells were treated with 10 nM PTX in the presence or absence of 3.2 mM
NAC. After 24 h treatment, cells were subjected to co-immunoprecipitation using antibody against Trx1. Results from one representative experiment were shown on the left. Quantitative
results of the interaction between Trx1 and FOXO1 were shown on the right. Data as mean values ± S.D. (n=3). *P b 0.05, **P b 0.01. (B) Interaction of exogenous FOXO1 and Trx1 pro-
teins. A2780 cells were transfectedwith the plasmids as indicated. At 36 h after transfection, cells were subjected to immunoprecipitation and western blotting analysis. Results from one
representative experimentwere shownon the left. Quantitative results of the interaction between FLAG–Trx1 andV5–FOXO1were shownon the right. Data asmeanvalues±S.D. (n=3).
**P b 0.01. (C) In vitro interaction between Trx1 and FOXO1 proteins. Left: a diagram showingﬁveGST–FOXO1 recombinant proteins. Upper right: A2780/PTX cell lysateswere subjected to
GST pull-down assay. Bottom right: GST andGST–FOXO1 recombinant proteinswere analyzed by coomassie blue staining. GST andGST–FOXO1 recombinant proteins at correctmolecular
mass were indicated by arrowheads.
401J. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 395–405catalase and GADD45 expressions. The increased expression of these
target genes was further enhanced by overexpression of Trx1. However,
this effect was signiﬁcantly compromised by the expression of Trx1
C69S mutant (Fig. 6A). These data suggested that Trx1 upregulated
the expressions of FOXO1 target genes and Trx1 cysteine 69was impor-
tant for the upregulation of FOXO1 target genes.
To further explore the mechanism underlying the regulation of
FOXO transcriptional activity by Trx1, we examined whether forced ex-
pression of Trx1 affected the binding of FOXO1 to the promoter of
MnSOD using ChIP assay. As shown in Fig. 6B, the binding of ectopically
expressed FOXO1 to the promoter of MnSOD was increased in A2780
cells transfected with wild type Trx1. However, Trx1 C69S mutant
abolished the upregulation of FOXO1 binding to MnSOD promoter.
These data suggested that Trx1–FOXO1 interaction might increase the
binding of FOXO1 to the promoter of its target genes.
3.7. Trx1/FOXO1 signaling pathway is involved in drug resistance in ovarian
cancer cells
To evaluate the biological signiﬁcance of Trx1/FOXO1 signaling path-
way in drug resistance in ovarian cancer cells, we assessed whetherTrx1-mediated drug resistance could be reversed by knocking down
FOXO1 in A2780 cells. As shown in Fig. 7A, overexpression of Trx1
protected A2780 cells from PTX-induced apoptosis by ﬂow cytometric
analysis using PI staining. This effect of Trx1 was abrogated by
cotransfection with FOXO1 shRNA. To further examine the importance
of the regulation of FOXO1 by Trx1 at cysteine 69 in drug resistance,
the effects of wild type Trx1 or Trx1 C69S mutant on FOXO1-mediated
drug resistance in A2780 cells were investigated. As expected, Trx1 sub-
stantially enhanced FOXO1-regulated drug resistance in A2780 cells.
However, Trx1C69Smutant almost completely abolished the regulation
of FOXO1-mediated drug resistance by Trx1 (Fig. 7C). These results
were further conﬁrmed by cleavage of poly(ADP-ribose) polymerase
(PARP), an apoptotic marker (Fig. 7B and D). Therefore, Trx1/FOXO1
signaling pathway might be involved in drug resistance in ovarian
cancer cells.
4. Discussion
Althoughmost ovarian cancers are responsive to PTX-based chemo-
therapy, cancer cells often develop drug resistance, which leads to treat-
ment failure and disease relapse. Thus, identiﬁcation of molecular
Fig. 6. Trx1 increases the expression of FOXO1 target genes. (A) Effects of Trx1 and Trx1 C69S mutant on the expression of FOXO1 target genes. A2780 cells were transfected with the
plasmids as indicated. After 36 h transfection, cells were harvested for expression of catalase, MnSOD, and Gadd45 using qRT-PCR. *P b 0.05, **P b 0.01. (B) Effects of Trx1 or Trx1 C69S
mutant on the binding of FOXO1 to the promoter of MnSOD gene. A2780 cells were transfected with plasmids as indicated for 36 h and harvested for ChIP assay. The density of PCR
bands from ChIP samples was normalized by that of the bands from the respective input samples. The relative ratio was determined by dividing the normalized values in lane 7, 8, and
9 by the value in lane 7.
402 J. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 395–405events that mediate drug resistance in ovarian cancer cells not only en-
hances our understanding of the biology of chemoresistance, but also
has signiﬁcant implications in designing more effective therapeutic
strategies which circumvent drug resistance. In the present study, we
revealed a key role of Trx1/FOXO1 signaling pathway in PTX-induced
chemoresistance in ovarian cancer cells. First, we showed that Trx1
and FOXO1 were overexpressed in PTX-resistant ovarian cancer
A2780 cells (A2780/PTX) compared with parental A2780 cells. The ac-
tivities and protein expression levels of Trx1 and FOXO1 proteins were
simultaneously induced by PTX in A2780 cells, but not in A2780/PTX
cells. Second, silencing of Trx1 or FOXO1 by shRNA increased sensitivity
to PTX in A2780/PTX cells. Third, we found that Trx1 bound to and in-
creased FOXO1 transcriptional activity. Trx1 increased FOXO1-induced
chemoresistance, while Trx1-induced chemoresistance was signiﬁcant-
ly inhibited by FOXO1 shRNA. Therefore, our study raised the possibility
that the regulation of FOXO1 by Trx1 was involved in PTX resistance in
ovarian cancer cells. FOXOs were reported to not only activate the apo-
ptotic machinery but also enhance cellular defenses and promote cell
survival according to different cell lines and various types or intensitiesof cellular stress response [21]. Here we provided evidence that FOXO1
acted as pro-survival effector molecules in PTX-induced cytotoxicity in
ovarian cancer cells.
Oxidative stress has been demonstrated to be involved in various
physiological and pathological processes, such as cancer [39]. The cell
growth and cell death could be linked to an intracellular ROS level
which might be ﬂuctuated in response to intracellular as well as extra-
cellular signals [40]. Several anticancer drugs resulted in a burst of
ROS to attack tumor cells, whichwas the potential mechanism of action
of the anticancer drugs [41,42]. However, the upregulation of antioxi-
dants and activation of redox-sensitive transcription factors mediating
survival signals were usually induced to counteract oxidative stress as
an adaptation response in cancer chemotherapy [43]. The balance be-
tween these two antagonizing signals ultimately determined when
and whether the stimulated cells would die. Our data showed that
ROS played an important role in the PTX-induced cytotoxicity in PTX-
sensitive A2780 cells, and correspondingly the activities of Trx1 and
FOXO1 proteins were upregulated by PTX-induced ROS. The upregula-
tion of Trx1 and FOXO1 might account for antagonizing PTX-induced
Fig. 7. Trx1/FOXO1 signaling pathwaymight be involved in PTX resistance in ovarian cancer cells. (A, B) Effects of knocking down FOXO1 on the anti-apoptotic protection of Trx1 in A2780
cells. (C, D) Effects of Trx1 and Trx1 C69Smutant on the FOXO1-mediated PTX resistance in A2780 cells. A2780 cells were transfected with the plasmids as indicated. After 36 h transfec-
tion, the cells were treated with or without 25 nM PTX. After 24 h treatment, the cells were harvested and subjected to apoptosis analysis (A, C) and western blotting analysis (B, D). The
number underneath each band in the immunoblot indicates the relative intensity of the corresponding band. Error bars indicate S.D. among three individual experiments. *P b 0.01.
403J. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 395–405oxidative damage in A2780 cells. In the meantime we provided evi-
dence that Trx1 upregulated expression of endogenous genes regulated
by FOXO1, including genes involved in antioxidant defense such as
MnSOD and catalase, and DNA damage repair such as Gadd45, whichFig. 8. A diagram depicts a hypothetical model wherein Trx1/FOXO1 signpromoted us to speculate that Trx1/FOXO1 signaling attenuated PTX
sensitivity through regulation of these target genes.
Trx1 and FOXO1 are located in both cytoplasm and nucleus. In this
paper, we found that PTX-induced ROS resulted in Trx1 and FOXO1aling pathway is involved in PTX resistance in ovarian cancer cells.
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Trx1 and FOXO1. Moreover, we found that the regulation of FOXO1
transcriptional activity by Trx1 depended on the cysteine residue at
position 69 of Trx1 since Trx1 C69S mutant attenuated FOXO1
transcriptional activity and the interaction between Trx1 and FOXO1.
In addition, Trx1 C69S mutant almost completely abolished the regula-
tion of FOXO1-mediated drug resistance by Trx1. Having excluded that
Trx1 redox status was responsible for Trx1 transcriptional activation,
the regulation of FOXO1 transcriptional activity might be associated
with the nuclear import of Trx1, as Trx1 C69Smutantwas barely detect-
ed in the nucleus. On the basis of these ﬁndings, we envisage a model
wherein PTX-resistant ovarian cancer cells are not sensitive to PTX
treatment since Trx1 and FOXO1 are overexpressed in these cells.
However in PTX-sensitive ovarian cancer cells, PTX treatment results
in ROS production to attack cancer cells, which induces Trx1 and
FOXO1 expressions and nuclear translocation to antagonize oxidative
stress. The ﬁnal outcome is that ROS levels might probably ascend
above a threshold to initiate PTX-induced tumor cell death (Fig. 8).
Whether Trx1 was S-nitrosylated in PTX-treated A2780 cells and the
role of Trx1 nuclear translocation in the regulation of FOXO1 transcrip-
tional activity need to be further elucidated.
In summary, this study showed a functional interaction between
Trx1 and FOXO1 that regulated drug resistance in ovarian cancer. Trx1
upregulated FOXO1 transcriptional activity and FOXO1-mediated drug
resistance and the effects might depend on Trx1 nuclear translocation
which was mediated by PTX-induced ROS. Thus, Trx1/FOXO1 pathway
might play an important role in the development of PTX resistance in
ovarian cancer.
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